Celldex shareholders approve equity plan increase, elect directors including Denice Torres

Celldex Therapeutics, Inc.

Stockholders approved 2M share increase to 2021 Omnibus Plan (total 9.5M shares) with 53.2M for, 963K against.
All 9 director nominees elected, including new director Denice Torres; Karen Shoos' term ended.
Ratification of PricewaterhouseCoopers as auditor for FY2025: 58M for, 119K against.
Advisory say-on-pay approved: 53.5M for, 627K against.
Harry Penner elected Chair of board post-meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.